| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 12/07/2024 | 22:59 | Business Wire | MorphoSys Announces Voluntary Delisting from the Nasdaq Global Market | NASDAQ:MOR | MorphoSys AG |
| 08/07/2024 | 14:03 | PR Newswire (US) | Kuehn Law Encourages DM, SHCR, MOR, and ALE Investors to Contact Law Firm | NASDAQ:MOR | MorphoSys AG |
| 20/06/2024 | 08:47 | Business Wire | MorphoSys and Novartis Sign Delisting Agreement and Intend to Implement a Merger Squeeze-out of MorphoSys’ Minority Shareholders | NASDAQ:MOR | MorphoSys AG |
| 10/06/2024 | 17:01 | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] | NASDAQ:MOR | MorphoSys AG |
| 04/06/2024 | 22:06 | Edgar (US Regulatory) | Form SC 14D9/A - Solicitation, recommendation statements: [Amend] | NASDAQ:MOR | MorphoSys AG |
| 29/04/2024 | 22:01 | Business Wire | MorphoSys AG Reports First Quarter 2024 Financial Results | NASDAQ:MOR | MorphoSys AG |
| 11/04/2024 | 14:39 | Business Wire | MorphoSys’ Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by Novartis | NASDAQ:MOR | MorphoSys AG |
| 13/03/2024 | 21:02 | Business Wire | MorphoSys AG Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update | NASDAQ:MOR | MorphoSys AG |
| 06/02/2024 | 12:14 | IH Market News | Boeing Faces Strike Threat, Palantir Up 18% After Recording its First Profitable Year, and More | NASDAQ:MOR | MorphoSys AG |
| 11/12/2023 | 01:31 | Business Wire | MorphoSys’ Pelabresib Improves All Four Hallmarks of Myelofibrosis in Phase 3 MANIFEST-2 Study | NASDAQ:MOR | MorphoSys AG |
| 20/11/2023 | 23:19 | Dow Jones News | MorphoSys Trial for Blood-Cancer Treatment Reaches Primary Endpoint | NASDAQ:MOR | MorphoSys AG |
| 20/11/2023 | 22:30 | Business Wire | MorphoSys’ Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom Reduction | NASDAQ:MOR | MorphoSys AG |
| 15/11/2023 | 22:01 | Business Wire | MorphoSys AG Reports First Nine Months and Third Quarter 2023 Financial Results | NASDAQ:MOR | MorphoSys AG |
| 09/08/2023 | 22:01 | Business Wire | MorphoSys AG Reports Second Quarter and First Half 2023 Financial Results | NASDAQ:MOR | MorphoSys AG |
| 03/05/2023 | 22:01 | Business Wire | MorphoSys AG Reports First Quarter 2023 Financial Results | NASDAQ:MOR | MorphoSys AG |
| 17/04/2023 | 13:37 | Business Wire | MorphoSys und Incyte präsentieren Fünf-Jahres-Ergebnisse der L-MIND-Studie, die bei Patienten mit rezidiviertem oder refraktärem DLBCL in Behandlung mit Monjuvi® (Tafasitamab-cxix) ein verlängertes, dauerhaftes Ansprechen zeigen | NASDAQ:MOR | MorphoSys AG |
| 17/04/2023 | 13:37 | Business Wire | Après cinq ans, MorphoSys et Incyte annoncent les résultats de l'étude L-MIND montrant des réponses prolongées et durables chez des patients atteints de LDGCB récidivant ou réfractaire traités par Monjuvi® (tafasitamab-cxix) | NASDAQ:MOR | MorphoSys AG |
| 16/04/2023 | 21:01 | Business Wire | MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi® (tafasitamab-cxix) | NASDAQ:MOR | MorphoSys AG |
| 15/03/2023 | 21:03 | Business Wire | MorphoSys AG Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update | NASDAQ:MOR | MorphoSys AG |
| 17/11/2022 | 22:25 | TipRanks | JMP Securities Sticks to Its Buy Rating for Morphosys Ag (MOR) | NASDAQ:MOR | MorphoSys AG |
| 16/11/2022 | 22:01 | Business Wire | MorphoSys AG Reports First Nine Months and Third Quarter 2022 Financial Results | NASDAQ:MOR | MorphoSys AG |
| 14/11/2022 | 11:30 | Dow Jones News | MorphoSys Shares Slide After Roche's Alzheimer's Drug Trial Fails | NASDAQ:MOR | MorphoSys AG |
| 11/08/2022 | 14:16 | TipRanks | J.P. Morgan Keeps Their Hold Rating on Morphosys Ag (MOR) | NASDAQ:MOR | MorphoSys AG |
| 04/08/2022 | 22:25 | TipRanks | JMP Securities Thinks Morphosys Ag’s Stock is Going to Recover | NASDAQ:MOR | MorphoSys AG |
| 03/08/2022 | 22:01 | Business Wire | MorphoSys AG Reports Second Quarter and First Half 2022 Financial Results | NASDAQ:MOR | MorphoSys AG |
| 15/06/2022 | 14:41 | PR Newswire (US) | I-Mab Partner MorphoSys Announces New License Agreements for Felzartamab and TJ210 | NASDAQ:MOR | MorphoSys AG |
| 14/06/2022 | 22:01 | Business Wire | MorphoSys and HIBio Enter Into Equity Participation and License Agreements for Felzartamab and MOR210 | NASDAQ:MOR | MorphoSys AG |
| 10/06/2022 | 09:15 | Business Wire | MorphoSys Presents Multiple Analyses of the MANIFEST Phase 2 Trial Investigating the Potential of Pelabresib in the Treatment of Myelofibrosis at EHA 2022 | NASDAQ:MOR | MorphoSys AG |
| 12/05/2022 | 16:45 | Business Wire | MorphoSys to Present New Data on Pelabresib and Monjuvi® (tafasitamab-cxix) at the 2022 European Hematology Association (EHA) and American Society of Clinical Oncology (ASCO) Annual Meetings | NASDAQ:MOR | MorphoSys AG |
| 05/05/2022 | 20:55 | TipRanks | Morphosys Ag (MOR) Receives a Buy from JMP Securities | NASDAQ:MOR | MorphoSys AG |